Stock Ratings / Health Care / PGNY / dividends

AGL (28) SHC (53) DVA (77) VMD (69) ⌘ Pro Terminal →

Progyny Inc. (PGNY) Dividend Safety Gauge & 10-Year DRIP Compounder

$28.40 +1.90% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $28.57

Progyny Inc. (PGNY) earns a Roarable Rating of B+ (Buy) with 77/100 RQD Confidence. High-quality cash engine (24% profit margin, 17% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 77/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.8% avg 90D alpha vs SPY • 70.3% hit rate) →

ROARABLE B+ • BUY Cap $2.18B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $28.56 (+0.58%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 14.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 77/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.8% avg 90D alpha vs SPY • 70.3% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+8.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PGNY)Realized 20D OHLCV Swing Band: ±7.4%

Deterministic 5-Pillar Attribution (77/100 Composite)

🔍 WHY PGNY SCORES 77/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+17/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 14.9% FCF Margin ($191.8M FCF) & 23.6% Gross Margin

▲ #2 Bullish Driver: Macro Regime Fit+16/20 pts (21% of score)

FRED Regime × Technicals: 72% of 52W Range • RSI-14 at 62 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Whale & Options Positioning13/20 pts (-7 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-7 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$27.93-3.8% Next Q

Q2 (-2Q)

Grade B$26.86+7.9% Next Q

Q3 (-1Q)

Grade B+$28.97-2% Next Q

Current

Grade B+$28.40+7.8% Hist 90D α

Trajectory: B- (69) → B+ (77)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PGNY Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 77/100 (B+) score, PGNY faces multiple-compression risk if 37.2x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 21.1% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($26.88) or 200D SMA ($24.36) invalidates the momentum regime and cuts Target Base ($30.83) toward Bear Floor ($23.29).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PGNY• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PGNY Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 77%NO 23%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (7.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $20,610

Est. Year-10 Shareholder Yield: $371/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.8K

Yr 1

$11.6K

Yr 2

$12.4K

Yr 3

$13.4K

Yr 4

$14.4K

Yr 5

$15.4K

Yr 6

$16.6K

Yr 7

$17.8K

Yr 8

$19.2K

Yr 9

$20.6K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in PGNY & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on PGNY and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PGNY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +52.85%⚡ TESTING RESISTANCE

2026-10-30O $28.66H $29.22L $28.30C $28.40VOL 807.7K

RES: $29.04SUP: $23.84SMA50: $26.88SMA200: $24.36

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PGNY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PGNY Butterfly Map → + Track PGNY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

28.5%/yr Implied 5Y Growth

vs. +10.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PGNY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PGNY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PGNY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PGNY)

Health Care Rank #29 of 1016 ⚔️ AGL vs PGNY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PGNY vs. AGL, SHC, DVA, VMD)

Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Progyny Inc. (PGNY) ranks #29 by composite RQD confidence (77/100, grade B+) and #248 by equity capitalization ($2.18B). Within this direct 5-issuer industry benchmark cohort, DVA leads on earnings valuation at 11.4x trailing P/E, while DVA leads on capital efficiency and profitability with 29.2% ROIC and — gross margin. PGNY currently leads its immediate peer cohort in composite quantitative strength at 77/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PGNY ACTIVE Progyny Inc.	B+	77/100	37.2x	23.6%	16.7%	+1.90%	$2.18B	Benchmark Subject
AGL agilon health inc.	E	28/100	—	—	-35.0%	-5.56%	$1.44B	/agl-vs-pgny →
SHC Sotera Health Company	D+	53/100	68.5x	55.5%	3.1%	+0.27%	$5.34B	/shc-vs-pgny →
DVA DaVita Inc.	B+	77/100	11.4x	—	29.2%	+5.10%	$12.33B	/dva-vs-pgny →
VMD Viemed Healthcare Inc.	C+	69/100	24.6x	57.5%	13.0%	-0.40%	$379.0M	/vmd-vs-pgny →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001551306

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Progyny Inc. (PGNY) reported GAAP revenue of $1.29B (+10.4% vs. FY2024 revenue of $1.17B , and +18.4% cumulative change since FY2023) , GAAP net income of $58.5M, operating cash flow of $210.2M, and free cash flow of $191.8M (+10.4% YoY). On the balance sheet, PGNY closed FY2025 with $742.4M in total assets against $0 in total debt (Altman Z-Score: 8.84, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.29B	$58.5M	$210.2M	$191.8M	$742.4M	—
FY2024 (FY)	2024-12-31	$1.17B	$54.3M	$179.1M	$173.7M	$607.1M	—
FY2023 (FY)	2023-12-31	$1.09B	$62.0M	$188.8M	$188.8M	—	—

3. PGNY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PGNY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Progyny Inc. (NASDAQ: PGNY) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $28.40 (+1.90% 1D, market cap $2.18B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, PGNY ranks #29 in composite RQD confidence.

How does PGNY compare to AGL and SHC in the Health Care sector?

Within the Health Care sector (Misc Health and Biotechnology Services), PGNY carries a Roarable B+ (77/100 RQD), trailing P/E of 37.2x, gross margin of 23.6%, and ROIC of 16.7%. By comparison, AGL (agilon health inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $1.44B) and SHC (Sotera Health Company) posts a D+ grade (53/100 RQD, P/E 68.5x, ROIC 3.1%, cap $5.34B). Among the 5-stock peer group, DVA leads on earnings multiple (11.4x) while DVA leads on capital efficiency (29.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PGNY?

Per PGNY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001551306), Progyny Inc. generated $1.29B in revenue (+10.4% YoY), $58.5M in net income, and $191.8M in free cash flow against $742.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (24% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PGNY trading relative to its 50-day, 200-day, and 52-week technical levels?

PGNY last traded at $28.40 (+1.90% on volume of 657,499 shares), positioning the stock +5.65% above its 50-day simple moving average ($26.88) and +16.58% above its 200-day simple moving average ($24.36). Across its 52-week range of $16.10 to $33.07, PGNY sits at the 72.5% percentile with a 14-day RSI of 62.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.4% ($26.30 to $30.50).

PGNY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does PGNY pay a dividend and is it safe?

Progyny Inc. (PGNY) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: PGNY RQD Cockpit PGNY 12M Forecast PGNY Earnings & Move PGNY Dividends & DRIP PGNY Insiders & 13F PGNY Whale Options PGNY Profit Sankey PGNY News & Why